Jazz Pharmaceuticals, Inc

VIVUS is a pharmaceutical company focused on the development and commercialization of new therapeutic products addressing obesity and sexual health, having its facilities in Mountain View, Calif. VIVUS has four products that are positioned to enter Phase 3 clinical trials, and one product that has completed Phase 3 evaluation, for which a new drug application has been submitted to the Food and Drug Administration. The pipeline includes QnexaTM, for which a Phase 2 study has been completed for the treatment of obesity, ALISTATM, for which a Phase 2B program is ongoing for the treatment of female sexual arousal disorder. Other products under development include Testosterone MDTS, for which a Phase 2 program has been completed for the treatment of hypoactive sexual desire disorder, and EvamistTM, for which a Phase 3 program has been completed for the treatment of menopausal symptoms. VIVUS has also developed and is marketing MUSE, a treatment for erectile dysfunction.

Nabi Biopharmaceuticals develops and markets products that fight serious medical conditions. The company focuses on developing products that address commercial opportunities. Its main business areas encompass Gram-positive bacterial infections, hepatitis, kidney disease and nicotine addiction. Nabi Biopharmaceuticals product brands include PhosLo, Nabi-HB and Aloprim along with a number of products in various stages of clinical and pre-clinical development. Nabi Biopharmaceuticals maintains its international headquarters in Boca Raton, Fla., with principal research and development offices and laboratories in Rockville, Md. The company's European headquarters, Nabi Biopharmaceuticals Europe Limited, is located in Bray, Ireland.

Napo Pharmaceuticals, Inc. is a San Francisco-based company dedicated to developing and commercializing prescription medicines that provide essential supportive care for individuals undergoing treatment for diseases like cancer. Their mission is to improve the comfort, quality of life, and dignity of patients experiencing treatment-related gastrointestinal distress, particularly overactive bowel symptoms such as chronic diarrhea, urgency, and incontinence. Napo Pharmaceuticals is currently focused on their Phase 3 pivotal OnTarget trial of Mytesi crofelemer, a preventative treatment for chemotherapy-induced overactive bowel, with comprehensive results expected in Q1 2024. They also support investigator-initiated studies exploring the potential of crofelemer for rare disease indications like short bowel syndrome and microvillus inclusion disease. Napo Pharmaceuticals takes pride in their responsible harvesting practices, sourcing their medicines from plants in rainforest regions. Their prescription medicines work through a novel mechanism of action, inhibitory modulation of two secretory chloride ion channels in the gastrointestinal tract. The company is committed to uncovering medical solutions to serve those in need, advancing their understanding through high-quality research conducted by external investigators. Environmental sustainability and social responsibility are paramount to Napo Pharmaceuticals, as they prioritize the responsible harvesting of their products and share benefits with the local communities that contribute to their mission.Generated from the website